The Fragility of ADCs: A Critical Analysis of China’s Biopharmaceutical Landscape
If you were to ask what the most fruitful achievement of China’s pharmaceutical industry has been over the past two years, ADC drugs would undoubtedly be considered “top-tier”. From the $2.6 billion licensing deal of Rongchang Biologics’ Vadastuximab in 2021, to the over $10 billion ADC collaboration between Kelun-Biotech and Merck in 2022, and then … Read more